Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edward Fruitman

Psychiatry Hewlett, NY Medical Doctor

NPI 1558434134 CMS profile 251815

1451 Broadway, Hewlett, NY 11557

Open in the dashboard

General payments

$430,970

1,292 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Edward Fruitman of Hewlett, NY is reported in the CMS Open Payments database as having received $430,970 across 1,292 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $101,302 256
2024 General $42,008 190
2023 General $96,574 213
2022 General $114,025 192
2021 General $39,494 166
2020 General $7,684 133
2019 General $29,882 142

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edward Fruitman
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Edward Fruitman were reported at $101,302. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Edward Fruitman Psychiatry median Middle half National median
2019 $29,882 $184 $59–$605 $163
2020 $7,684 $119 $36–$372 $114
2021 $39,494 $143 $43–$576 $132
2022 $114,025 $153 $50–$590 $149
2023 $96,574 $170 $56–$651 $160
2024 $42,008 $179 $57–$673 $164
2025 $101,302 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Neurocrine Biosciences, Inc. $112,686 271 payments
  2. Teva Pharmaceuticals USA, Inc. $82,969 181 payments
  3. Allergan Inc. $80,118 199 payments
  4. AbbVie, Inc. $78,571 181 payments
  5. Alkermes, Inc. $35,189 84 payments
  6. E.R. Squibb & Sons, L.L.C. $29,603 81 payments
  7. Idorsia Pharmaceuticals US Inc $4,785 2 payments
  8. Lumenis BE inc $1,366 1 payment
  9. Axsome Therapeutics, Inc. $622 41 payments
  10. ITI, Inc. $611 34 payments
  11. Other $4,450 217 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $373,920 188 payments
  2. Food and Beverage $28,794 992 payments
  3. Consulting Fee $18,625 6 payments
  4. Travel and Lodging $9,341 99 payments
  5. Education $290 7 payments
Products named General payments · program years 2019–2025
  1. INGREZZA Neuropsychiatry $78,330 181 payments
  2. UZEDY $77,485 125 payments
  3. VRAYLAR Neuroscience $31,258 65 payments
  4. LYBALVI Cns $27,693 59 payments
  5. LYBALVI Cns $27,417 42 payments
  6. LYBALVI Cns $27,267 32 payments
  7. LYBALVI Cns $27,267 32 payments
  8. COBENFY $26,694 52 payments
  9. VRAYLAR Neuroscience $26,204 80 payments
  10. INGREZZA Neurology $17,564 59 payments
  11. Other $73,656 708 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 81 drugs

Part D claims

3,943

Median for Psychiatry & Neurology: 100

Drug cost

$1,644,120

Median for Psychiatry & Neurology: $2,986

Branded share of claims

25.6%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 86 $671,713
Invega Trinza Paliperidone Palmitate Brand 17 $181,350
Aristada Aripiprazole Lauroxil Brand 43 $143,553
Vraylar Cariprazine Hcl Brand 80 $123,818
Uzedy Risperidone Brand 42 $120,883
Abilify Maintena Aripiprazole Brand 37 $100,655
Lybalvi Olanzapine/Samidorphan Malate Brand 28 $45,134
Invega Sustenna Paliperidone Palmitate Brand 17 $45,027
Mounjaro Tirzepatide Brand 19 $23,470
Lurasidone Hcl Generic 47 $23,454

The 10 drugs with the highest cost, of 81 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UZEDY
$21,033 42 —
VRAYLAR
$5,695 80 —
INGREZZA
$426 86 —
COBENFY
$288 — —
CAPLYTA
$164 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

1,292 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record